Aptuit acquires Kuecept, expands formulation services

By Melissa Fassbender

- Last updated on GMT

Aptuit has acquired Kuecept to help meet customer demand. (Image: iStock)
Aptuit has acquired Kuecept to help meet customer demand. (Image: iStock)
Aptuit has acquired Kuecept to help meet demand for specialist drug pre-formulation, formulation prototyping, and formulation development services.

London-based Kuecept offers CRO services supporting preclinical drug development, specifically, pre-formulation testing, preclinical dose-vehicle screening, and formulation development, in addition to various drug-delivery technologies.

Through this acquisition, our customers can now combine our capabilities with Aptuit's full suite of integrated drug development solutions to facilitate the transition of new drugs through preclinical evaluation to clinical manufacture​,” said Dr. Mark Saunders, CEO and founder of Kuecept.

Per the acquisition, Kuecept will also provide Aptuit with its knowledge in respiratory, parenteral, and oral formulation development for insoluble compounds.

"We offer solutions in the fields of integrated drug discovery, CMC, and preclinical biosciences. The acquisition of Kuecept enhances our scientific expertise and capabilities in the pre-formulation development space​,” said Aptuit CEO Dr. Jonathan Goldman.

Goldman explained that Kuecept scientists use small milligram quantities of API in the de-risking phase of late stage discovery. “Technologies such as hot melt extrusion, spray drying, wet and dry micronization and cutting edge microsphere chemistry are all routinely performed on very small amounts of API to develop robust and practical formulations​,” he added.

According to Goldman, the acquisition will allow Aptuit to “improve the transition of compounds from medicinal chemistry in discovery through to formal regulatory based Drug Product Development.​"

The addition of these new capabilities will help grow Aptuits’ “unique fully integrated candidate​” to IND/CTA solution (INDiGO​) – the company’s program for accelerating early drug candidates.

Additionally, Goldman expects the acquisition will help customer benefit from “improved solubility solutions, reduced drug attrition and associated reductions in time and development costs​."

Related news

Related products

show more

Powered by Ingredients + Innovation

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA | 07-Oct-2024 | Product Brochure

In partnership with our industry-leading supplier partners, Univar Solutions Pharmaceutical Ingredients is proud to introduce Powering Healthy Tomorrows.

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us

Products

View more

Webinars